廣告
香港股市 將收市，收市時間：5 小時 57 分鐘

  • 恒指

    17,802.35
    -287.58 (-1.59%)
     

  • 國指

    6,368.68
    -108.56 (-1.68%)
     

  • 上證綜指

    2,952.71
    -19.81 (-0.67%)
     

  • 滬深300

    3,458.21
    -22.06 (-0.63%)
     

  • 美元

    7.8068
    -0.0022 (-0.03%)
     

  • 人民幣

    0.9305
    +0.0005 (+0.05%)
     

  • 道指

    39,127.80
    +15.64 (+0.04%)
     

  • 標普 500

    5,477.90
    +8.60 (+0.16%)
     

  • 納指

    17,805.16
    +87.50 (+0.49%)
     

  • 日圓

    0.0484
    +0.0001 (+0.21%)
     

  • 歐元

    8.3460
    +0.0077 (+0.09%)
     

  • 英鎊

    9.8580
    +0.0020 (+0.02%)
     

  • 紐約期油

    80.53
    -0.37 (-0.46%)
     

  • 金價

    2,309.10
    -4.10 (-0.18%)
     

  • Bitcoin

    60,896.61
    -1,435.43 (-2.30%)
     

  • CMC Crypto 200

    1,267.85
    -15.94 (-1.24%)
     

CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Equity Research
·2 分鐘文章

For the quarter ended March 2024, CareDx (CDNA) reported revenue of $72.05 million, down 6.7% over the same period last year. EPS came in at -$0.03, compared to -$0.11 in the year-ago quarter.

The reported revenue represents a surprise of +13.24% over the Zacks Consensus Estimate of $63.63 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +84.21%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

廣告

Here is how CareDx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Patient and digital solutions: $9.62 million compared to the $9.64 million average estimate based on two analysts. The reported number represents a change of +11.6% year over year.

  • Revenue- Testing services: $53.84 million versus the two-analyst average estimate of $46.42 million. The reported number represents a year-over-year change of -12.9%.

  • Revenue- Product: $8.59 million versus the two-analyst average estimate of $7.39 million. The reported number represents a year-over-year change of +25.3%.

View all Key Company Metrics for CareDx here>>>

Shares of CareDx have returned +9.9% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CareDx, Inc. (CDNA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research